Ian Walters EIR Mediqventures
Ian Walters, M.D., M.B.A. is the Entrepreneur in Residence at Medqiventures and is part-time CMO of Intensity Therapeutics. Over his 16 year career, he demonstrated both leadership and expertise in drug development, including the advancement of multiple cancer compounds from research stages through approval.
Ian specializes in the evaluation, prioritization, and the innovative development of new therapies for the treatment of severe diseases. He has worked at Protein Design Labs, Millenium Pharmaceuticals, and Sorrento Therapeutics leading corporate development, translational medicine, clinical development and medical affairs.
Ian spent seven years at Bristol-Myers Squibb (BMS), where he managed physicians overseeing the international development of >8 oncology compounds (including Nivolimab (anti-PD-1), Ipilimumab (anti-CTLA-4), brivanib (anti VEGF/FGF), anti-IGF/IR, VEGFR2 biologic, Elotuzimab(antiCS1), as well as biomarker and companion diagnostic work. He also was a core member of the Strategic Transactions Group evaluating and executing licensing agreements, mergers and acquisitions, clinical collaborations, and the company’s immuno-oncology strategy.
Before entering the private sector, Ian was a lead investigator at the Rockefeller University and initiated cutting edge immunology research to understand the mechanism of action of several compounds. Ian received his MD from the Albert Einstein College of Medicine and an MBA from the Wharton School of The University of Pennsylvania.